JP2019014758A5 - - Google Patents

Download PDF

Info

Publication number
JP2019014758A5
JP2019014758A5 JP2018206547A JP2018206547A JP2019014758A5 JP 2019014758 A5 JP2019014758 A5 JP 2019014758A5 JP 2018206547 A JP2018206547 A JP 2018206547A JP 2018206547 A JP2018206547 A JP 2018206547A JP 2019014758 A5 JP2019014758 A5 JP 2019014758A5
Authority
JP
Japan
Prior art keywords
composition
optionally substituted
cancer
dutpase
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018206547A
Other languages
English (en)
Japanese (ja)
Other versions
JP6660993B2 (ja
JP2019014758A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019014758A publication Critical patent/JP2019014758A/ja
Publication of JP2019014758A5 publication Critical patent/JP2019014758A5/ja
Application granted granted Critical
Publication of JP6660993B2 publication Critical patent/JP6660993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018206547A 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤 Active JP6660993B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361749791P 2013-01-07 2013-01-07
US61/749,791 2013-01-07
US201361874643P 2013-09-06 2013-09-06
US61/874,643 2013-09-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015551794A Division JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2019014758A JP2019014758A (ja) 2019-01-31
JP2019014758A5 true JP2019014758A5 (enExample) 2019-05-09
JP6660993B2 JP6660993B2 (ja) 2020-03-11

Family

ID=50030487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015551794A Active JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤
JP2018206547A Active JP6660993B2 (ja) 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015551794A Active JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤

Country Status (7)

Country Link
US (3) US9809571B2 (enExample)
EP (1) EP2941423B1 (enExample)
JP (2) JP6450323B2 (enExample)
CN (1) CN105189478B (enExample)
CA (1) CA2914178C (enExample)
IL (1) IL239827B (enExample)
WO (1) WO2014107622A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189478B (zh) 2013-01-07 2019-10-22 南加州大学 脱氧尿苷三磷酸酶抑制剂
WO2015103489A1 (en) 2014-01-03 2015-07-09 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
EP3319939B1 (en) * 2015-07-08 2024-11-27 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
WO2018098207A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098209A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
UA123810C2 (uk) 2017-01-23 2021-06-02 Цадент Терапеутікс, Інк. Модулятори калієвих каналів
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
EP4171549B1 (en) 2020-06-26 2026-03-25 CV6 Therapeutics (NI) Limited Combination therapy with deoxyuridine triphosphatase inhibitors
WO2022197978A1 (en) * 2021-03-17 2022-09-22 President And Fellows Of Harvard College Compositions and methods for modulating mitochondrial function and biogenesis

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4829785B1 (enExample) 1970-03-26 1973-09-13
BE787766A (fr) * 1971-08-21 1973-02-19 Merck Patent Gmbh Imides d'acide glutarique et leur procede de preparation
US4063019A (en) 1976-03-30 1977-12-13 E. R. Squibb & Sons, Inc. [[[(2,4-Dioxo-1-imidazolidinyl)amino]carbonyl]amino]-acetylcephalosporin derivatives
US4304715A (en) 1979-06-08 1981-12-08 Derek Hudson Enkephalin analogues
DE3027596A1 (de) 1980-07-21 1982-02-18 Bayer Ag, 5090 Leverkusen Triazolidin-3,5-dion-oxyalkylverbindungen und verfahren zu ihrer herstellung
JPS5839672A (ja) 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
JPH0674251B2 (ja) 1986-02-07 1994-09-21 全薬工業株式▲会▼社 ビス−ジオキソピペラジン誘導体
JPS63101361A (ja) * 1986-09-08 1988-05-06 ブリティッシュ・テクノロジー・グループ・リミテッド ジオキソピペリジン誘導体を含有する不安解消組成物
FR2644786B1 (fr) 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
CA2200964A1 (en) 1994-11-24 1996-05-30 Takeda Chemical Industries, Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor
WO1997036916A1 (en) 1996-03-29 1997-10-09 The University Of Medicine And Dentistry Of New Jersey dUTPASE, ITS ISOFORMS, AND DIAGNOSTIC AND OTHER USES
JPH09286786A (ja) 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
EP1045836B1 (en) 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
JP2002541138A (ja) 1999-04-02 2002-12-03 デュポン ファーマシューティカルズ カンパニー マトリックスメタロプロテアーゼ、TNF−α、およびアグレカナーゼの阻害剤としての新規アミド誘導体
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
KR20030082990A (ko) 2001-03-15 2003-10-23 아스트라제네카 아베 메탈로프로테이나제 억제제
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
WO2002083651A2 (en) 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003249812A1 (en) 2002-07-18 2004-02-09 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2004011448A1 (en) 2002-07-25 2004-02-05 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
AR052196A1 (es) 2005-01-25 2007-03-07 Celgene Corp Metodos y composiciones que utilizan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona
WO2006135763A2 (en) 2005-06-09 2006-12-21 The Johns Hopkins University Inhibitors of dna repair enzymes and methods of use thereof
BRPI0714880A2 (pt) 2006-07-24 2013-05-21 Gilead Sciences Inc inibidores da transcriptase reversa do hiv
EP1939186A1 (en) 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
KR101384940B1 (ko) 2008-06-03 2014-04-11 다이호야쿠힌고교 가부시키가이샤 인간 데옥시우리딘 트리포스파타아제 저해 활성을 갖는 신규 우라실 화합물 또는 그 염
WO2010025308A2 (en) 2008-08-27 2010-03-04 Universtiy Of Southern California Inhibitors of dutpase
JP2011231015A (ja) * 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー/エス 第viii因子の修飾
WO2010149761A1 (en) 2009-06-25 2010-12-29 Bioversys Gmbh Composition for treatment of tuberculosis
JP2013032293A (ja) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトdUTPase阻害活性を有する5−フルオロウラシル化合物又はその塩
WO2011065541A1 (ja) * 2009-11-30 2011-06-03 大鵬薬品工業株式会社 抗腫瘍効果増強剤
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2834199C (en) 2011-07-18 2020-01-07 Merck Patent Gmbh Benzamides as allosteric modulators of the fsh receptor
UA111861C2 (uk) 2011-11-15 2016-06-24 Такеда Фармасьютікал Компані Лімітед Ароматична гетероциклічна сполука дигідрокси
CN105189478B (zh) 2013-01-07 2019-10-22 南加州大学 脱氧尿苷三磷酸酶抑制剂
WO2015103489A1 (en) 2014-01-03 2015-07-09 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2016175324A1 (ja) 2015-04-30 2016-11-03 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
RU2686722C1 (ru) 2015-05-01 2019-04-30 Тайхо Фармасьютикал Ко., Лтд. Новые кристаллы урацильного соединения
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
EP3319939B1 (en) 2015-07-08 2024-11-27 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Similar Documents

Publication Publication Date Title
JP2019014758A5 (enExample)
US10604526B2 (en) Chemokine receptor modulators and uses thereof
SA521431048B1 (ar) مركبات بيروليدين
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2017502967A5 (enExample)
JP2019517487A5 (enExample)
JP2016505621A5 (enExample)
JP2011509949A5 (enExample)
JP2013502430A5 (enExample)
MX2023009857A (es) Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
JP2017537882A5 (enExample)
JP2008535902A5 (enExample)
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
JP2017511378A5 (enExample)
JP2019535723A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019505529A5 (enExample)
JP2020520957A5 (enExample)
JP2018507257A5 (enExample)
JP2013538213A5 (enExample)
MX2025004221A (es) Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos
JP2008508287A5 (enExample)
JP2011518168A5 (enExample)
WO2016205460A4 (en) Polycyclic derivatives targeting ral gtpases and their therapeutical applications
JP2015500267A5 (enExample)